LifeAire Systems’ Founder and CEO, Dr. Kathryn C. Worrilow, is speaking at InterPhex 2019 in New York City to raise visibility to the cytotoxic role that airborne volatile organic compounds, or VOCs, play in critical life sciences cleanroom environments—such as those supporting the living cell in gene cell and immunotherapy manufacturing.
Over 15 years of the study of the role airborne biological and chemical pathogens exert in epigenetic variation and molecular epidemiology have defined the airborne metrics necessary to support the culture of highly sensitive cellular products across all cell processing operations. The remediation of all airborne bacterial, viral, and chemical pathogens support a consistent living cell culture environment thereby optimizing critical metrics of cell potential, viability, loss, and clinical delivery.
Evidence will be presented to illustrate the negative impact of airborne chemical and viable particulate contaminants on cellular and regenerative medicine processes critical in healthcare and life science facilities. Current GMP metrics do not address cytotoxic levels of VOCs and viable particulates present in the processing space. An understanding of why it is critical to exceed GMP metrics to achieve optimal cell growth in life science facilities will be discussed.
LifeAire Systems’ patented, multi-stage air purification technologies allow such facilities to eliminate up to 99.99% of all known biological and chemical contaminants, thus comprehensively removing the toxic influence of airborne contaminants resulting in statistically significant increases in cellular metrics and the delivery of successful cellular products to the patient, thereby offering an improved level of patient care.
LifeAire is presenting in two key programs during the conference, a presentation on Tuesday morning and a panel discussion on Wednesday afternoon.
Join Our Presentation – Tuesday, April 2, 10:30am
A Transformational Living Cell Environment: A Paradigm Shift in Personalized Medicine that Provided the Most Comprehensive Protection Across all Cell Culture/Processing Operations
Tuesday, April 2, 2019 | 10:30am – 11:15am | Stage 2, Booth 1577, Exhibit Hall
Presented by Kathryn C. Worrilow, PhD, LifeAire Systems
Attendees will learn how definitive control of all sources of ambient air can optimize the facilities of the future using recent and well-defined environmental metrics for the culture of the living cell. This knowledge is based upon 15 years of the study of the role of biological and chemical pathogens in epigenetic variation and molecular epidemiology. The research defined the airborne metrics necessary to support the culture of highly sensitive cellular products across all cell/processing operations. The remediation of all airborne bacterial, viral, and chemical pathogens supports a consistent living cell culture environment thereby optimizing critical metrics of cell potential, viability, loss, and clinical delivery.
Evidence will be presented to examine the chemical and viable particulate airborne contaminants that negatively impact cellular and regenerative medicine processes critical in healthcare and life science facilities. Current GMP metrics do not address cytotoxic levels of VOCs and viable particulates present in the processing space. An understanding of why it is critical to exceed GMP metrics to achieve optimal cell growth in life science facilities will be discussed.
A roadmap for addressing known or detected environmental issues interfering with the optimal healthcare and life science manufacturing facilities will be discussed. Comprehensive control of ambient air provides an optimized clinical, in vitro living cell/tissue culture and processing environment thereby improving cell processing protocols, cell viability, yield and efficacy. Details will be discussed that will allow the implementation of defined cellular metrics necessary to support similar-sensitive needs of a pharmaceutical processing and manufacturing environment and offer a paradigm shift in the current GMP-driven environment.
Join Our Thought-Leadership Panel Discussion – Wednesday, April 3, 2:15pm
Wednesday, April 3, 2019 | 2:15pm – 3:00pm | INTERPHEX Live Crystal Palace Lobby
Join one of the global leading experts in the role of cytotoxic VOCs to the gene/cell therapy process, Dr. Kathryn C. Worrilow, CEO and Founder LifeAire Systems—provider of patented technology that is designed to neutralize up to 99.99% of all biological and chemical contaminants that adversely affect cleanroom environments.
Discussion topics will span a range top questions facing gene-cell therapy and CAR-T development platforms, including focus on how companies can enhance their protocols for Gene/ Cell Therapy success, and how they can mitigate VOCs within their cleanroom environments. Questions include what airborne metrics dramatically impact successful CAR-T Cell outcomes, what can owners do to determine the quality of air within their lab/manufacturing environments, what data supports the negative affect VOCs have on successful outcomes of cell development, and what is next on the CAR-T horizon.
- Russ Somma, Ph.D., SommaTech Consulting President & Founder – moderator
- Kathryn C. Worrilow, Ph.D., Founder and CEO, LifeAire Systems
- Ali Mohamed, Ph.D., VP CMC, Immatics Biotechnologies
- Boro Dropulic, Ph.D., Chief Science Officer and General Manager, Miltenyi Biotec
- Avery D. Posey, Jr., Ph.D., Instructor, Pathology and Laboratory Medicine, University of Pennsylvania
- Peter Olagunju, Vice President Patient Operations & Lentiglobin Program Leader, Bluebird Bio
- Heidi Hagen, Chief Strategy Officer, Vineti Inc.
This panel is a continuation of last year’s successful InterPhex LIVE 2018 discussion: Emerging and Transformational Technologies in Personalized Medicine – A Paradigm Shift. Click to view a video recording of that discussion.
Recognition from InterPhex 2018
In 2018, LifeAire was chosen the winner of InterPhex’s Editor’s Choice award, sponsored by Pharmaceutical Processing, representing the best in exhibiting in Knowledge, Innovation, and Technologies within the pharma and biopharma industries.